These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 17363548

  • 1. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB.
    Clin Cancer Res; 2007 Mar 15; 13(6):1911-25. PubMed ID: 17363548
    [Abstract] [Full Text] [Related]

  • 2. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.
    Clin Cancer Res; 2005 Sep 01; 11(17):6390-9. PubMed ID: 16144944
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.
    Cancer Res; 2001 Jul 15; 61(14):5355-61. PubMed ID: 11454674
    [Abstract] [Full Text] [Related]

  • 4. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
    Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE, Scott AM.
    Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):572-8. PubMed ID: 20638193
    [Abstract] [Full Text] [Related]

  • 5. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK.
    Cancer Res; 2001 Jul 15; 61(14):5349-54. PubMed ID: 11454673
    [Abstract] [Full Text] [Related]

  • 6. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
    Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM, Johns TG.
    Oncogene; 2004 Aug 12; 23(36):6095-104. PubMed ID: 15221011
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6732-43. PubMed ID: 15475464
    [Abstract] [Full Text] [Related]

  • 8. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
    Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW, Scott AM.
    Proc Natl Acad Sci U S A; 2003 Dec 23; 100(26):15871-6. PubMed ID: 14676326
    [Abstract] [Full Text] [Related]

  • 9. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ.
    Cancer Res; 1995 Jul 15; 55(14):3140-8. PubMed ID: 7606735
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor.
    Bender H, Takahashi H, Adachi K, Belser P, Liang SH, Prewett M, Schrappe M, Sutter A, Rodeck U, Herlyn D.
    Cancer Res; 1992 Jan 01; 52(1):121-6. PubMed ID: 1727372
    [Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas.
    Tysnes BB, Haugland HK, Bjerkvig R.
    Invasion Metastasis; 1997 Jan 01; 17(5):270-80. PubMed ID: 9876221
    [Abstract] [Full Text] [Related]

  • 12. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H, Shi B, Zhang Q, Jiang H, Hu S, Kong J, Yao M, Yang S, Li Z.
    FASEB J; 2012 Jan 01; 26(1):73-80. PubMed ID: 21917986
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
    Fan Z, Baselga J, Masui H, Mendelsohn J.
    Cancer Res; 1993 Oct 01; 53(19):4637-42. PubMed ID: 8402640
    [Abstract] [Full Text] [Related]

  • 14. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
    Kozer N, Kelly MP, Orchard S, Burgess AW, Scott AM, Clayton AH.
    Biochemistry; 2011 May 10; 50(18):3581-90. PubMed ID: 21495621
    [Abstract] [Full Text] [Related]

  • 15. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF, Reist CJ, Bigner DD, Zalutsky MR.
    Cancer Res; 2000 Aug 15; 60(16):4453-60. PubMed ID: 10969792
    [Abstract] [Full Text] [Related]

  • 16. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.
    Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ.
    Cancer Res; 1996 Sep 01; 56(17):3859-61. PubMed ID: 8752145
    [Abstract] [Full Text] [Related]

  • 17. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
    Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C.
    Cancer Res; 1994 Apr 01; 54(7):1695-701. PubMed ID: 8137284
    [Abstract] [Full Text] [Related]

  • 18. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H, Moroyama T, Mendelsohn J.
    Cancer Res; 1986 Nov 01; 46(11):5592-8. PubMed ID: 3756906
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
    Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK.
    J Immunol; 2011 Sep 15; 187(6):3383-90. PubMed ID: 21832160
    [Abstract] [Full Text] [Related]

  • 20. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
    Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM.
    Int J Cancer; 2002 Mar 20; 98(3):398-408. PubMed ID: 11920591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.